ANI Pharmaceuticals Inc SVP and CFO Stephen P. Carey filed a Form 4 on September 1, 2026, disclosing the sale of 2,850 shares of common stock on August 31, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Stephen P. Carey, SVP and CFO of ANI Pharmaceuticals Inc (NASDAQ:ANIP)
- Shares sold: 2,850 shares of common stock disposed of on August 31, 2026
- Weighted average price: $72.8 per share, with individual trades ranging from $71.89 to $73.36
- Beneficial ownership after transaction: 171,843 shares held directly
- Trading plan: Sales were effected pursuant to a Rule 10b5-1 plan adopted March 6, 2026
- Transaction code: S (sale), executed as a direct ownership transaction
Stephen P. Carey's Share Sale Details and Remaining Ownership in ANI Pharmaceuticals
According to the filing, Stephen P. Carey, identified as SVP and CFO of ANI Pharmaceuticals Inc, disposed of 2,850 shares of the company's common stock on August 31, 2026. The transaction was coded "S" in Table I of the Form 4, indicating an open-market sale. The filing notes that the shares were sold in multiple trades at prices ranging from $71.89 to $73.36, with the weighted average sales price reported as $72.8 per share.
The filing discloses that the sales were "effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026." Rule 10b5-1 plans allow corporate insiders to establish pre-scheduled trading arrangements at a time when they are not in possession of material nonpublic information. The Form 4 checkbox confirms the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following the reported transaction, the filing states that Carey beneficially owned 171,843 shares of ANI Pharmaceuticals common stock directly. No derivative securities transactions were reported in Table II. The Form 4 was signed on September 1, 2026, by attorney-in-fact Meredith W. Cook on behalf of Stephen P. Carey.
What Was Disclosed
The filing reports a single sale of 2,850 common shares by ANI Pharmaceuticals' SVP and CFO on August 31, 2026, at a weighted average price of $72.8, executed under a Rule 10b5-1 plan adopted March 6, 2026, leaving him with 171,843 shares directly held.




Please wait processing your request...